Feel Therapeutics

Feel Therapeutics occupies a specialized position at the intersection of digital biomarkers, mental-health monitoring, medical devices, and digital therapeutics. Its differentiation is the attempt to convert continuous physiological and digital signals into objective measures for clinical trials, real-world studies, medication support, and care delivery. That approach contrasts with mental-health workflows that rely heavily on episodic questionnaires and self-reporting. The company’s product set spans Feel 360 for continuous monitoring, Feel DTx for personalized digital interventions, Feel RxPal for medication adherence and engagement, Feel Well for stress and sleep support, and Feel RPM for remote monitoring. Feel’s focus is narrower than broad consumer wearables and more clinically oriented than general wellness platforms. Its competitive challenge is demonstrating that proprietary biomarkers produce reliable, actionable outcomes and can be integrated into regulated clinical and pharmaceutical workflows. The $13.83 million funding base and 11-to-50 employee range indicate a focused specialist rather than a scaled category leader.

Feel Therapeutics has followed a long product-development trajectory since its 2015 founding, with George Eleftheriou and Haris Tsirmpas remaining in senior roles after more than a decade of company building. Initial financing included $1.8 million in Seed funding announced in 2018 and $4.5 million in a 2019 Seed round led by Felicis Ventures. The company then added a $4.2 million Venture Round in 2022 and convertible notes of $2.5 million in 2023 and $830,000 in 2024. A further convertible-note round was announced on Apr 23, 2025, although its amount is undisclosed. Across six rounds, total funding is listed at $13.83 million. The product strategy has broadened from a wearable and passive-monitoring foundation into a portfolio covering clinical research, digital therapeutics, medication adherence, wellbeing, and remote patient monitoring. The 2024 public unveiling of an AI-enabled wearable and the 2025 Nebius AI Discovery Awards suggest continued investment in machine-learning infrastructure and healthcare applications.